Abstract
The HIV Research for Prevention (HIVR4P) conference is dedicated to advancing HIV prevention research, responding to a growing consensus that effective and durable prevention will require a combination of approaches as well as unprecedented collaboration among scientists, practitioners, and community workers from different fields and geographic areas. The conference theme in 2018, “From Research to Impact,” acknowledged an increasing focus on translation of promising research findings into practical, accessible, and affordable HIV prevention options for those who need them worldwide. HIVR4P 2018 was held in Madrid, Spain, on 21–25 October, with >1,400 participants from 52 countries around the globe, representing all aspects of HIV prevention research and implementation. The program included 137 oral and 610 poster presentations. This article presents a brief summary of highlights from the conference. More detailed information, complete abstracts as well as webcasts and daily Rapporteur summaries may be found on the conference website.
Highlights
Opening plenary talks, delivered by Linda-Gail Bekker (Abstract PL01.01)[1], Anthony Fauci (Abstract PL01.03),[1] and Sheena McCormack (Abstract PL01.02),[1] provided important perspectives on the major challenges facing the HIV prevention field
The HIV Research for Prevention (HIVR4P) conference is dedicated to advancing HIV prevention research, responding to a growing consensus that effective and durable prevention will require a combination of approaches as well as unprecedented collaboration among scientists, practitioners, and community workers from different fields and geographic areas
HIVR4P 2018 was held in Madrid, Spain, on 21–25 October, with >1,400 participants from 52 countries around the globe, representing all aspects of HIV prevention research and implementation
Summary
Opening plenary talks, delivered by Linda-Gail Bekker (Abstract PL01.01)[1] (recipient of the 2018 Desmond Tutu Award for HIV Prevention Research and Human Rights), Anthony Fauci (Abstract PL01.03),[1] and Sheena McCormack (Abstract PL01.02),[1] provided important perspectives on the major challenges facing the HIV prevention field Presenting his long-term vision for control of the pandemic, Dr Fauci introduced the image of two roads converging toward eventual control. HIVR4P included a wealth of presentations exploring our growing knowledge of immune responses, updates from studies currently underway, views of strategies to improve the results of RV144, and an examination of the growing pipeline of vaccine approaches. These include broadly neutralizing antibodies (bNAbs) and CD8+ T-cell pathways to a vaccine, and DNA, RNA, and mosaic strategies. The leading immunogen in this category, the fusion peptidebased immunogen FP8_v1-rTTHC, will begin clinical trials in 2019 led by the NIH VRC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
